Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Arbuck, S. G.
Right arrow Articles by Cheson, B. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Arbuck, S. G.
Right arrow Articles by Cheson, B. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 8:S119-S128, 1997
© 1997 European Society for Medical Oncology

New drugs in non-Hodgkin's lymphoma*

S. G. Arbuck, J. M. Sorensen, M. C. Christian, P. Ho, J. M. Pluda and B. D. Cheson

Cancer Therapy Evaluation Program, Division of Cancer Treatment, Diagnosis and Centers, National Cancer Institute Bethesda, MD, USA

1Correspondence to: Dr. Susan G. Arbuck Investigational Drug Branch National Cancer Institute Executive Plaza North Room 715 Bethesda, MD 20892 USA

While novel agents designed to target molecular abnormalities involved in lymphoma pathogenesis are most likely to improve current therapeutic results, cytotoxic therapy remains the main stay of therapy. Several new chemotherapy agents, including purine antimetabolites, taxanes, camptothecins, suramin, and protein kinase C inhibitors, are discussed. Other issues important in lymphoma drug development, including the limited patient population available for evaluation of investigational agents, are also considered.

bryostatin, chemotherapy, cladrabine, docetaxel, fludarabine, 506U, irinotecan, lymphoma, 9-aminocamptothecin, paclitaxel, suramin, topotecan

* The US Government right to retain a non-exclusive, royalty-free licence in and to any copyright is acknowledged.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.